VeCollal® / Corpowell secures Investment from Seventure Partners (Health for Life Capital™) to Accelerate Expansion of Plant-Based Collagen Alternative
- VeCollal® technology, based on biomimetic science, sets a new standard for sustainability and results in the ingestible beauty and nutraceuticals sector.
- Clinical Breakthrough with -20.1% Reduction in Visible Cellulite to be presented at Fi Europe
Fi Europe, December 2–4, Paris Expo Porte de Versailles, Paris, Booth 72J25
PARIS, FRANCE – December 2, 2025 – VeCollal®, developed by Corpowell, today confirms an investment by Seventure Partners (via Health For Life Capital™) at the Fi Europe exhibition in Paris. The company simultaneously announces a clinical breakthrough with a -20.1% reduction in visible cellulite, opening up the market to cosmetic companies. With these milestones, VeCollal® positions itself as the leading, science-backed player in the rapidly growing nutraceuticals market. VeCollal® is presenting its complete portfolio of biomimetic, 100% plant-based Type I and Type II collagen alternatives, which are setting the new industry standard.
VeCollal® is presenting its complete portfolio at Fi Europe, featuring Type I (skin, hair, bones) and Type II (cartilage, joints) formulas. Both are supported by robust clinical studies and patent-pending, sustainable technology. VeCollal® is the world's first clinically proven, plant-based biomimetic. It mimics the natural amino acid profile of human collagen one-to-one. This results in a superior, bio-identical foundation, which distinguishes VeCollal® from incomplete animal collagen and simple 'boosters' on the market.
Visible Results in 8 Weeks with Only 5 Grams Per Day
The core of VeCollal®’s innovation lies in its efficiency and effectiveness. Where animal collagen often requires 10–20 grams/day, VeCollal® Type I delivers visible results with just 5 grams per day over 8 weeks, including a 32.9% reduction in wrinkle depth. This is thanks to the combination of the perfect biomimetic structure and AI-driven genetic activation. In-vitro studies show that the formula stimulates fibroblasts—the key cells in the skin that produce collagen—to increase collagen secretion (production) by +135%. The VeCollal® Type II formula works in a similar, AI-driven manner to support cartilage and joint function.
Tony Van Campen, CEO and Founder of Corpowell: "As a former athlete, I know the importance of the right building blocks for the body. Throughout my career in the sector, I noticed we blindly accepted animal collagen, despite it being an incomplete protein. We decided to raise the bar: VeCollal® is the result of our passion to create a perfect, biomimetic, 100% plant-based alternative that is, moreover, better."
Exclusive: -20.1% Reduction in Visible Cellulite
VeCollal® is also unveiling the results of an independent, double-blind study (Trial S036-Etichub University of Pavia, Italy) that investigated the superficial alteration of cellulite in 60 adult women over 56 days. The results show that VeCollal® has a net effect of -20.10% reduction in the volume of superficial alteration (cellulite) in 56 days. This is a strategic milestone that opens the market for co-branding with major cosmetic and ingestible beauty brands for Corpowell, the company behind VeCollal®.
VeCollal® / Corpowell Secures Investment from Seventure for Global Expansion
Corpowell, spearheaded by VeCollal®, is committed to exponential growth following a successfulinvestment round led by Seventure Partners, a European leader in Venture Capital, Growth & Private Equity. VeCollal® has already secured robust early momentum with strategic partnerships in the United States and Europe, including co-branding projects with prominent brands such as Feel, Ringana, Aroma-Zone, Solaray, and Life Extension. The capital injection validates the biomimetic technology and accelerates global rollout.
Isabelle de Cremoux, CEO of Seventure Partners: "We believe in the transition to sustainable, AI-driven Health Tech, Nutrition and Food solutions. The VeCollal® technology is not only substantially more CO2-efficient than animal collagen, but the company also has a scalable, B2B model with strong traction in the United States, Asia, and Europe. Our investment is intended to accelerate the global rollout and establish VeCollal® as the leading brand in biomimetic high value, protein alternative ingredients."
Corpowell targets a 10× revenue growth by 2028 to become the dominant European player.
Ethics, Ecology, and Efficiency: 83% Less CO₂ Thanks to Fermentation
VeCollal® eliminates the ethical and ecological challenges of animal collagen. The Life Cycle Assessment (LCA) of VeCollal® confirms that its fermentation-based process has an 83% lower CO₂ emission compared to traditional animal collagen. Thanks to this proven sustainability and the absence of ethical concerns regarding animal welfare, VeCollal® demonstrably helps brands achieve their ESG (Environmental, Social, Governance) objectives and minimize supply chain risks. Furthermore, the use of fermented plant-based amino acids guarantees a halal/kosher-suitable, allergen-free, non-GMO, and traceable ingredient. This fully meets Clean Label requirements, making VeCollal® the perfect partner for transparent and pure products.
Tony Van Campen, CEO and Founder of Corpowell: "For me, VeCollal® is about removing the choice between ethics and results. Consumers want sustainability and proven effectiveness. By replicating the amino acid structure of human collagen and activating its production in the body, we offer an intelligent alternative that genuinely makes a difference. That is the definition of Collagen 2.0 for us."
END OF PRESS RELEASE
Appendix: Whitepaper: The studies that change the collagen conversation
VeCollal Whitepaper 090925.pdf
PDF 3.8 MB
The VeCollal® LCA: Carbon Footprint and Sustainability Commitment
VeCollal® is 83% more CO2-efficient in the production of its raw materials than traditional, animal (bovine) collagen. This has been demonstrated through a comparative analysis of the carbon footprint of amino acids versus conventional collagen, based on CarbonCloud figures.
Core Raw Material Difference: The massive CO₂ reduction is the direct result of VeCollal®’s animal-free, fermentation-based production process. This avoids the significant ecological footprint and methane emissions associated with livestock farming, the primary source of bovine collagen. The CO₂ impact of subsequent transport is comparable for both types of collagen.
Ethical & Clean Label Guarantee: The use of plant-based, fermented amino acids guarantees a halal/kosher-suitable, allergen-free, non-GMO, and traceable ingredient.
Positive Impact & Offsetting: Corpowell goes beyond the raw material comparison and offsets the CO₂ emissions from transport through a partnership with Trees for All. This actively contributes to reforestation projects in Europe and Madagascar.
Facts & Figures
Market Dynamics: Hypergrowth:
- The total vegan collagen market is growing at a CAGR of 30–36%, compared to 8–10% for traditional collagen, confirming the rapid shift towards plant-based, scientific alternatives.
- Europe leads in the number of new collagen products, although the USA is the largest market, followed by Asia and the EU.
VeCollal® in numbers:
- Clinical Proof: -32.9% reduction in wrinkles over 8 weeks. This is stronger than most published animal collagen studies.
- New Results: -20.1% reduction in visible cellulite, opening the market to cosmetic companies.
- Efficiency: Requires only 5 grams/day to achieve clinically proven results, in contrast to the 10–20 grams often required for animal collagen.
- Innovation: Causes a +135% increase in collagen secretion in human skin fibroblasts within 48 hours.
- Type II Result: -58% improvement in WOMAC score for joint pain/mobility.
- Sustainable: Production emits 83% less CO₂ compared to animal collagen.
Clinical Trial Highlights
VeCollal® is the most science-backed vegan collagen technology on the market. Corpowell has heavily invested in clinical and in vitro studies to prove the superiority of its biomimetic approach.
Type I (Skin, Beauty & Anti-Aging):
- In Vitro Activity: Fibroblasts showed a 135% increase in collagen secretion after 48 hours of VeCollal® Type I exposure.
- Clinical Results (Gold Standard IRB Study): In a double-blind, randomized, placebo-controlled study with 90 subjects, and a second study with 60 subjects:
- Wrinkle Reduction: Average -32.9% wrinkle depth in just 8 weeks.
- Cellulite: -20.1% reduction in visible cellulite (University of Pavia, publication pending).
- Skin Improvement: +21% improvement in hydration and -13.1% reduction in roughness.
Type II (Joints, Mobility & Bones):
- Focused on mimicking human cartilage collagen (Type II) with AI-driven activation.
- Clinical Results (Preview): Initial trials showed a -58% improvement in the WOMAC score (medical score for joint pain, stiffness, and mobility).
Perscontact
Would you like more information? Please reach out to book a 1-on-1 meeting with Tony Van Campen, CEO of Corpowell, at the Fi Europe exhibition (Paris) or to schedule an online interview.
Saartje Dietvorst
Saskia Castelyns
About Corpowell
Corpowell is an innovation company in the nutraceuticals and clean beauty industry, founded by Tony Van Campen. The company is the developer and owner of VeCollal®, the world's first scientifically proven, biomimetic, and vegan collagen alternative. Corpowell's mission is to create superior, sustainable, plant-based supplements. The company utilizes AI-driven biochemical engineering and works with international brands.
About Tony Van Campen, CEO and Founder of Corpowell
Tony Van Campen is the CEO and founder of Corpowell, the company behind VeCollal®. His background as a former professional athlete and his experience in the supplements industry led to the founding of VeCollal®. He identified a crucial gap in the market: the need for a science-backed, vegan, and ethical alternative to animal collagen. Van Campen's mission is to establish a biomimetic plant-based collagen as the new scientific standard.
About Dr. Josué Jiménez Vázquez, Scientific Lead Partner VeCollal®
Dr. Josué Jiménez Vázquez, PhD is the scientific force and R&D partner behind VeCollal®’s biomimetic technology. As a prominent skin tissue engineer and professor with expertise in tissue regeneration, he combined AI-driven biochemical engineering with the market vision.
About Seventure Partners
Seventure Partners is a long-term equity investor who actively supports innovative companies aiming at generating positive impacts on People, Society, Sustainability and the Planet.
With ~€1b net commitments under management as of the end of 2024, Seventure is a leading venture capital firm in Europe investing since 1997 in innovative businesses with high growth potential in two main fields: (i) Life Sciences (biotechnology, health & digital health, nutrition, foodtech, blue economy, aquaculture, animal feed, agriculture, sport & wellness…) with a particular focus on the microbiome, across Europe, Israel, Asia, Australia and North America, and (ii) Digital Technologies (fintech, retailtech, cybersecurity, etc.) in Europe, mainly France and Germany.
Seventure’s investments can range between €500k and €10m per round, or up to €20m per company, to support the development of companies from creation (seed and first round) to development capital financing rounds (venture, growth, pre-IPO and IPO).
In the field of Life Sciences, Seventure invests mainly in “classic” approaches, such as drugs, medical devices and diagnostics, and industrial biotechnology, as well as “beyond the pill” approaches, such as digital health, preventive medicine, well-being, personalised medicine, nutrition and food, with a particular interest in the applications of discoveries related to the microbiome and foodtech.
With Health for Life Capital™ funds I, II, III and its co-investments funds, Seventure is a worldwide leader in microbiome and nutrition investments with more than 30 companies in its portfolio to date.
The Health for Life Capital™ funds have attracted strategic investments from prestigious organizations including Danone, Novartis, two US-based global food ingredient providers (to be disclosed), Lesaffre, Tornier, Tereos, Unigrains and Bel, as well as financial institutions, family offices and entrepreneurs.
For more details: http://www.seventure.fr/en X: @seventurep